GlobalData Healthcare, Author at Clinical Trials Arena

19 Oct 2020

Comment

Trials disrupted due to Covid-19 continue to resume

19 Oct 2020

14 Oct 2020

Comment

Positive vote from FDA’s Advisory Committee for Alkermes’ ALKS-3831 strengthens its potential position in the Schizophrenia market

14 Oct 2020

12 Oct 2020

Comment

Covid-19 Vaccine Development Across the Globe

12 Oct 2020

Comment

AstraZeneca’s quick Covid-19 vaccine trial restart splits experts

12 Oct 2020

Comment

Eli Lilly’s and Regeneron’s EUA talk trigger prudence on available Covid-19 data

12 Oct 2020

Comment

Kala’s dry eye syndrome steroid likely to be FDA approved; mixed potential on uptake

12 Oct 2020

01 Oct 2020

Comment

Overall clinical trial disruption due to Covid-19 declines, but the number of trials with slow recruitment continues to grow

01 Oct 2020

30 Sep 2020

Comment

New frontiers in the treatment of metastatic urothelial carcinoma raises hopes for patients and their families

30 Sep 2020

29 Sep 2020

Comment

vTv’s azeliragon study for Alzheimer’s disease and type 2 diabetes has support but some scepticism remains

29 Sep 2020

28 Sep 2020

Comment

EASD 2020: New Results from the EMPEROR-Reduced Trial Demonstrate the Efficacy of Empagliflozin in the Treatment of Heart Failure With or Without Type 2 Diabetes

28 Sep 2020

Sections

Most Read

Most Recent

The big interview: Cisco UK and Ireland CEO David Meads

Most Read

Featured

In 2020, OCT Europe is celebrating its 10th anniversary. Join us at our virtual conference

Sections

Most Read

Featured

Aptinyx reports positive data from Phase II trial of NYX-783 for PTSD

Most Read

Featured

In 2020, OCT Europe is celebrating its 10th anniversary. Join us at our virtual conference

Most Read

Featured

In 2020, OCT Europe is celebrating its 10th anniversary. Join us at our virtual conference

Sections

Most Read

Featured

SynapCon

GlobalData Healthcare

Trials disrupted due to Covid-19 continue to resume

Positive vote from FDA’s Advisory Committee for Alkermes’ ALKS-3831 strengthens its potential position in the Schizophrenia market

Covid-19 Vaccine Development Across the Globe

AstraZeneca’s quick Covid-19 vaccine trial restart splits experts

Eli Lilly’s and Regeneron’s EUA talk trigger prudence on available Covid-19 data

Kala’s dry eye syndrome steroid likely to be FDA approved; mixed potential on uptake

Overall clinical trial disruption due to Covid-19 declines, but the number of trials with slow recruitment continues to grow

New frontiers in the treatment of metastatic urothelial carcinoma raises hopes for patients and their families

vTv’s azeliragon study for Alzheimer’s disease and type 2 diabetes has support but some scepticism remains

EASD 2020: New Results from the EMPEROR-Reduced Trial Demonstrate the Efficacy of Empagliflozin in the Treatment of Heart Failure With or Without Type 2 Diabetes

Sections

Most Read

Most Recent

Most Read

Featured

Sections

Most Read

Featured

Most Read

Featured

Most Read

Featured

Sections

Most Read

Featured

Join Our Newsletter